All In Biotech

Drug Trial Radar · NCT03736967

Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis

A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Assess the Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Nov 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingRandomized with 206 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

206

Actual

Start

Nov 12, 2018

Primary completion

Mar 13, 2020

Study completion Jul 28, 2020

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
Collaborators
Sanofi
First posted
Nov 9, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study is to evaluate the efficacy of REGN3500 monotherapy compared with placebo treatment in adult patients with moderate-to-severe Atopic dermatitis (AD). Secondary Objectives are to: * Evaluate the efficacy of REGN3500 in combination with dupilumab compared with placebo treatment in adult patients with moderate-to-severe AD * Assess the safety, tolerability, and immunogenicity of subcutaneous (SC) doses of REGN3500 monotherapy and REGN3500 in combination with dupilumab in adult patients with moderate-to-severe AD * Evaluate the Pharmacokinetic (PK) of REGN3500 monotherapy and REGN3500 in combination with dupilumab in adult patients with moderate-to-severe AD

Conditions

  • Atopic Dermatitis

Interventions

  • REGN3500Drug

    Administered subcutaneous (SC) every 2 weeks (q2w)

  • DupilumabDrug

    Administered SC q2w

  • REGN3500 + Dupilumab ComboDrug

    Administered SC q2w

  • PlaceboDrug

    Administered SC q2w

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score Based on Observed Values Set to Missing After Rescue Treatment at Week 16Time frame: Week 16

Locations

66 sites in 7 countries. Site status is shown where the registry gives one.

  • Regeneron Research Site

    Phoenix, Arizona

  • Regeneron Research Site

    Fountain Valley, California

  • Regeneron Research Site

    Long Beach, California

  • Regeneron Research Site

    Los Angeles, California

  • Regeneron Research Site

    Los Angeles, California

  • Regeneron Research Site

    Sacramento, California

  • Regeneron Research Site

    Davie, Florida

  • Regeneron Research Site

    Sandy Springs, Georgia

  • Regeneron Research Site

    Rockville, Maryland

  • Regeneron Research Site

    Bay City, Michigan

  • Regeneron Research Site

    Saint Joseph, Michigan

  • Regeneron Research Site

    Troy, Michigan

  • Regeneron Research Site

    Forest Hills, New York

  • Regeneron Research Site

    New York, New York

  • Regeneron Research Site

    New York, New York

  • Regeneron Research Site

    The Bronx, New York

  • Regeneron Research Site

    High Point, North Carolina

  • Regeneron Research Site

    Norman, Oklahoma

  • Regeneron Research Site

    Portland, Oregon

  • Regeneron Research Site

    Pittsburgh, Pennsylvania

  • Regeneron Research Site

    Arlington, Texas

  • Regeneron Research Site

    Richmond, Virginia

  • Regeneron Research Site

    Anderlecht, Belgium

  • Regeneron Research Site

    Antwerp, Belgium

  • Regeneron Research Site

    Brussels, Belgium

  • Regeneron Research Site

    Brussels, Belgium

  • Regeneron Research Site

    Liège, Belgium

  • Regeneron Research Site

    Loverval, Belgium

  • Regeneron Research Site

    Brno, Czechia

  • Regeneron Research Site

    Pardubice, Czechia

  • Regeneron Research Site

    Prague, Czechia

  • Regeneron Research Site

    Prague, Czechia

  • Regeneron Research Site

    Bad Bentheim, Germany

  • Regeneron Research Site

    Berlin, Germany

  • Regeneron Research Site

    Halle, Germany

  • Regeneron Research Site

    Hamburg, Germany

  • Regeneron Research Site

    Hamburg, Germany

  • Regeneron Research Site

    Hanau, Germany

  • Regeneron Research Site

    Leipzig, Germany

  • Regeneron Research Site

    Lübeck, Germany

Showing 40 of 66 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.